To The Moon

On March 20, 2026, Beiersdorf issued another public statement. While the first part of the statement focuses on the results related to Thiamidol®630, we make no comment on their product claims. However, the latter part again refers to KT-939 and selectively interprets the International Search Report (ISR) and Written Opinion issued during the PCT international application process (PCT/CN2025/091903). To ensure that consumers and investors have an accurate understanding of the situation, Kintor Pharmaceutical hereby clarifies the following: The PCT International Search Report is a preliminary reference opinion. Substantive examination by national patent offices has not yet begun, and it does not constitute a final determination on patent grant. Under the global framework of the Patent Coope

Kintor Pharmaceutical has noted the announcement made yesterday by Beiersdorf AG regarding the innovation achievements of THIAMIDOL®630 and fair competition. The statement specifically mentioned Suzhou Kintor Pharmaceuticals and our core product KT-939. We hereby issues the following statement: Since theestablishment, Kintor Pharmaceutical has always been a science-driven and rigorously innovative company. KT-939 is a proprietary cosmetic ingredient independently developed by our company, and protected by intellectual property rights. Its experimental data were published last year in a top international cosmetics journal, including comparative results with earlier products of the same mechanism (including THIAMIDOL®630). As a novel cosmetic ingredient entering

Suzhou, 17 March, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Suzhou Kintor Pharmaceuticals, Inc. ( “Suzhou Kintor”), a wholly-owned subsidiary of the Company, entered into the exclusive strategic cooperation framework agreement (the “Framework Agreement”) in the cosmetics sector with Shanghai Chicmax Cosmetic Co., Ltd. (a company listed on The Stock Exchange of Hong Kong Limited (stock code: 2145), “Chicmax”) in relation to the rapid commercialization of the Company’s whitening and freckle-removing functional cosmetic raw material KT-939. Chicmax, a multi-brand beauty company listed on The Stock Exchange of Hong Kong Limited (stock code: 2145), focuses on research and development, manufacturing and sales of mass skin care, maternal, baby

Recently, Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Suzhou Kintor Pharmaceuticals, Inc. ( the “Suzhou Kintor”), a wholly-owned subsidiary of the Company, entered into the personal care products dealership agreement (the “Dealership Agreement”) with the Guangzhou Wanlu Chemical Co., Ltd. ("Wanlu Chemical") and Shanghai Fangdeng Chemical Co., Ltd. ("Fangdeng Chemical") (collectively referred to as "Manner Chemical") respectively in relation to the dealership authorisations of the Company’s whitening and freckle-removing functional cosmetic raw material KT-939 and the consensus of target sales volumes for the next three years. Pursuant to the Dealership Agreement, the Suzhou Kintor authorizes Wanlu Chemical as a dealers

In the newly announced entry list of the Inspiration Hive zone at the 2025 New York Society of Cosmetic Chemists (NYSCC) exhibition, Kintor’s innovative ingredient KT-939 has been selected as the only "Chinese ingredient" among the numerous global ones. It will compete with global industry giants such as Ashland, DSM-Firmenich, and Eastman, marking a groundbreaking milestone that China’s cosmetic ingredient R&D stands at the forefront of global innovation. The 2025 NYSCC exhibition will open from 3rd June to 4th June at the Jacob Javits Convention Center in New York. As the world’s most influential B2B beauty industry event, NYSCC consistently sets trends for the global beauty and personal care sector, focusing on the integration of raw material supply chains and the communication

Suzhou, 29 October, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed KT-939 has recently received the review approval of the International Nomenclature Cosmetic Ingredient (the “INCI”) by the International Cosmetic Ingredient Nomenclature Committee with assigned Mono ID of 39815. KT-939 is a tyrosinase inhibitor under development by the Company, effectively inhibiting the melanin production with antioxidant and anti-inflammatory effects. If melanocytes produce an excessive amount of melanin, it may lead to skin pigmentation problems. Tyrosinase is a key rate-limiting enzyme in the synthesis of melanin, and inhibiting its activity can curb the production of melanin from the source. The previous enzymology and cellular melanoge

Suzhou, July 10, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that after receiving the designation for its in-house developed KX-826 from the International Nomenclature Cosmetic Ingredient (the “INCI”), the Company’s cosmetics with KX-826 as the main ingredient was officially launched into the international market recently. The first product is the topical anti-hair loss solution for androgenetic alopecia (the “AGA”).  The Company will further explore the efficacy of KX-826 in the field of AGA and acne, actively enrich the product lines, increase market promotion to target users and meet customer requirements under different usage scenarios. The Company is of the view that the launch of the New Product will provide a solid stream of revenue and cash

Suzhou, June 5, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed KX-826 has recently received the International Nomenclature Cosmetic Ingredient (the “INCI”) review approval from the International Cosmetic Ingredient Nomenclature Committee. The assigned INCI name is Methylpyridinyl Fluoromethoxybenzonitrile Dimethyloxothiooxoimidazolidine. INCI names are systemic names recognized worldwide for the identification of cosmetic ingredients and are cited by product labeling regulations in many countries. The assignation would facilitate the global launch of the Company's functional cosmetics with KX-826 as the main ingredient. About Kintor Pharmaceutical Limited Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and c

Suzhou, May 24, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the clinical trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of male adult androgenetic alopecia (“AGA”) in China (the “Clinical Trial”) was cleared by the National Medical Products Administration (the “NMPA”) recently.  The Clinical Trial is aimed to evaluate the efficacy and safety of KX-826 tincture 1.0% for the topical treatment of male adults with AGA in China. The Company’s preclinical studies have shown that the KX-826 tincture 1.0% has significantly increased the retention concentration of the tincture on h

2024 American Association of Cancer Research Annual Meeting (AACR 2024) will be held from April 5-10, 2024, in San Diego, United States. As the focal point of the cancer research community globally, countless latest scientific and medical studies in tumor field are first published here every year. In AACR 2024, one study of drug candidate GT0486 and two pre-clinical studies (including an anti-PD-1/ALK-1 bispecific antibody Nivo813 and a molecular glue GT19870) from Kintor Pharma are selected. It demonstrates high research and development value of drug and pre-clinical studies, also signifies that the company’s innovative capabilities and potential for drug development have been internationally recognized. The abstracts are available on AACR’s official website. Abstracts： GT0486（mTORC1/2） T